0001415889-25-008117.txt : 20250314 0001415889-25-008117.hdr.sgml : 20250314 20250314163825 ACCESSION NUMBER: 0001415889-25-008117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250312 FILED AS OF DATE: 20250314 DATE AS OF CHANGE: 20250314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Megna Michael R CENTRAL INDEX KEY: 0001464583 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25740836 MAIL ADDRESS: STREET 1: 1050 HINGHAM STREET CITY: ROCKLAND STATE: MA ZIP: 02370 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 4 1 form4-03142025_080322.xml X0508 4 2025-03-12 0001730430 Kiniksa Pharmaceuticals International, plc KNSA 0001464583 Megna Michael R 23 OLD BOND STREET, THIRD FLOOR LONDON X0 W1S 4PZ UNITED KINGDOM false true false false CHIEF ACCOUNTING OFFICER 1 Class A Ordinary Share 2025-03-12 4 M 0 9051 11.10 A 35579 D Class A Ordinary Share 2025-03-12 4 S 0 9051 22.45 D 26528 D Share Option 11.10 2025-03-12 4 M 0 9051 0 D 2032-04-06 Class A Ordinary Share 9051 13763 D This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.45 and $22.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. /s/ Madelyn Zeylikman, Attorney-in-Fact 2025-03-14